Identification of plasma Complement C3 as a potential biomarker for neuroblastoma using a quantitative proteomic approach
Patrick Y. Kim(Children's Cancer Institute Australia), Belamy B. Cheung(Children's Cancer Institute Australia)
Cited by 22
Related Papers
TRIM16 Acts as an E3 Ubiquitin Ligase and Can Heterodimerize with Other TRIM Family Members
|PLoS ONE|2012|115
TRIM16 acts as a tumour suppressor by inhibitory effects on cytoplasmic vimentin and nuclear E2F1 in neuroblastoma cells
|Oncogene|2010|70
High TDP43 expression is required for TRIM16-induced inhibition of cancer cell growth and correlated with good prognosis of neuroblastoma and breast cancer patients
|Cancer Letters|2016|64